InterMed Discovery Receives Michael J. Fox Foundation Award for IMD-026259
PD is a disease of progressive neuro-degeneration where the cells of particular brain regions involved in the production of dopamine die progressively in a process involving “oxidative stress”. The oxidative stress seen in PD is caused by dysfunctional mitochondria activating the downstream signal protein HIF-1. Therefore negative regulation of the HIF-1 signal is thought to be a valid therapeutic strategy towards reduction of neurotoxicity mediated by oxidative stress and subsequent neuro-inflammation. IMD’s naturally based product candidate IMD-026259 inhibits HIF-1 and has already demonstrated potent neuro-protective capabilities in several biological models including PD.
“Due to its innovative point of intervention, we consider IMD-026259 to be a novel disease-modifying therapeutic approach to oxidative stress related, neuro-inflammatory diseases such as PD,” said Philipp Wabnitz, Head Pharmacology at InterMed Discovery.
“These funds will enable us to further substantiate preclinical proof of principle towards development of this promising product candidate,“ said Dr. Thomas Henkel, co-Managing Director of InterMed Discovery.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.